What Bicara Therapeutics (BCAX) Said on Its Q3 Earnings Call
Bicara Therapeutics NASDAQ: BCAX said its pivotal study of FICERA in a form of advanced head and neck cancer has reached sufficient enrollment to support a planned top-line interim analysis in mid-2027.…
● GlobeNewsWireNov 9, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Bicara Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Achieved substantial enrollment in FORTIFI-HN01 pivotal trial in 1L R/M HPV-negative HNSCC; topline results from interim analysis expected in mid-2027 Enrolling FORTIFI-FLEX alternate dosing study; expect to have data b…
● GlobeNewsWireNov 4, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, tod…
● GlobeNewsWireNov 2, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Bicara Therapeutics to Report Third Quarter 2026 Financial Results and Business Updates on November 9, 2026, at 8:30 AM ET
BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, tod…
Bicara Therapeutics (NASDAQ:BCAX) Given Buy Rating at BTIG Research
Bicara Therapeutics (NASDAQ: BCAX - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at BTIG Research in a research report issued on Monday, Benzinga reports. They currently have a $39.00 tar…
● GlobeNewsWireOct 5, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, tod…
● GlobeNewsWireSep 3, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, to…
Article counts from the last market-wide feed page, across every symbol we track and not just BCAX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.